Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTRIS: Real World Study of AZD9291 in EGFR T790M+ NSCLC
NCT02474355Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2015
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02474355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02474355.